Abstract
Introduction/AimUrinary biomarkers are increasingly recognized as important indicators of renal injury in type 2 diabetes mellitus (T2DM), and some may also serve as early predictors of microvascular complications. Diabetic kidney disease (DKD) is the most common microvascular complication of type 2 diabetes mellitus and a leading cause of chronic kidney disease and end-stage renal failure. Although microalbuminuria is the established early marker of renal injury, its limited sensitivity and specificity necessitate novel urinary biomarkers for earlier detection. This study aimed to assess whether urinary type IV collagen, transferrin, and liver-type fatty acid–binding protein (L-FABP) could serve as early biomarkers of DKD and to evaluate their association with diabetic retinopathy.
MethodsEighty T2DM patients were divided into two groups: normoalbuminuric (≤30 mg/day) and microalbuminuric (30–300 mg/day). Ten healthy individuals served as controls. All participants were older than 18 years, had diabetes duration >1 year, and an estimated glomerular filtration rate (eGFR) >60 ml/min/1.73 m². Urinary concentrations of type IV collagen, transferrin, and L-FABP were measured in 24-hour and first-morning urine samples using ELISA. Statistical analyses included group comparisons, correlation testing, and receiver operating characteristic (ROC) curve assessment.
ResultsUrinary levels of all biomarkers were negligible in controls but significantly higher in microalbuminuric compared with normoalbuminuric patients (p < 0.05). Type IV collagen showed the highest diagnostic accuracy (90.4%) for early DKD. All biomarkers correlated positively with DKD, while urinary transferrin was additionally associated with diabetic retinopathy
ConclusionUrinary type IV collagen, transferrin, and L-FABP are promising early biomarkers of diabetic kidney disease, demonstrating superior diagnostic potential to albuminuria. Moreover, urinary transferrin may serve as a noninvasive marker for early detection of diabetic retinopathy, supporting its role in monitoring microvascular complications in T2DM
Keywords
References
The published articles will be distributed under the Creative Commons Attribution 4.0 International License (CC BY). It is allowed to copy and redistribute the material in any medium or format, and remix, transform, and build upon it for any purpose, even commercially, as long as appropriate credit is given to the original author(s), a link to the license is provided and it is indicated if changes were made. Users are required to provide full bibliographic description of the original publication (authors, article title, journal title, volume, issue, pages), as well as its DOI code. In electronic publishing, users are also required to link the content with both the original article published in Journal of Medical Biochemistry and the licence used.
Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.